Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 1/20 | 0.53 |
| ▸ | HRH1 | P35367 | 2/20 | 0.50 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | PTAFR | P25105 | 3/20 | 0.44 |
| ▸ | TBXAS1 | P24557 | 7/20 | 0.43 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1120385 | 0.81 | AOC3 (0.55) | L3MBTL1 | |
| SCHEMBL11454463 | 0.79 | CYP2A6 (0.59) | CYP2A6HRH1CHRNA7TDP1L3MBTL1 | |
| SCHEMBL29485675 | 0.73 | TDP1 (0.80) | CYP2A6HRH1CHRNA7TDP1L3MBTL1 | |
| SCHEMBL29485677 | 0.73 | CYP2A6 (0.76) | CYP2A6HRH1CHRNA7TDP1L3MBTL1 | |
| SCHEMBL2843094 | 0.73 | CYP2A6 (0.76) | CYP2A6HRH1CHRNA7TDP1L3MBTL1 | |
| SCHEMBL724788 | 0.73 | TDP1 (0.80) | CYP2A6HRH1CHRNA7TDP1L3MBTL1 | |
| SCHEMBL11846860 | 0.73 | CHRNA7 (0.79) | CYP2A6HRH1CHRNA7TDP1L3MBTL1 | |
| SCHEMBL1120399 | 0.72 | DAO (0.39) | L3MBTL1 | |
| SCHEMBL1120558 | 0.72 | AOC3 (0.47) | HRH1 | |
| SCHEMBL8658187 | 0.71 | HRH1 (0.81) | CYP2A6HRH1CHRNA7TDP1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9469641-B2 | Pyrido[3,4-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-10-18 | — | — | US | disclosed |
| US-9260429-B2 | Pyrido[3,4-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2016-02-16 | — | — | US | disclosed |
| US-20130190323-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-25 | — | — | US | disclosed |
| US-20130184306-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-20130131077-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130079352-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2013-03-28 | — | — | US | disclosed |
| US-8338447-B2 | Pyrido[3,4-B]indoles and methods of use | MEDIVATION TECHNOLOGIES, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| EP-2280968-A2 | PYRIDO [3, 4-B]INDOLES AND METHODS OF USE | Medivation Technologies, Inc. (US) | 2011-02-09 | — | — | EP | disclosed |
| US-20090270412-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. | 2009-10-29 | — | — | US | disclosed |
| WO-2009120717-A2 | PYRIDO [3, 4-B] INDOLES AND METHODS OF USE | MEDIVATION TECHNOLOGIES, INC. (US) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184306-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | CYP2A6 949/4885HRH1 64/4885CHRNA7 60/4885 |
| US-20130079352-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | CYP2A6 949/4885HRH1 64/4885CHRNA7 60/4885 |
| US-20090270412-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | CYP2A6 949/4885HRH1 64/4885CHRNA7 60/4885 |
| US-20130190323-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR4, HTR2C | CYP2A6 949/4885HRH1 64/4885CHRNA7 60/4885 |
| US-20130131077-A1 | PYRIDO[3,4-B]INDOLES AND METHODS OF USE | HTR3B, HTR2C, HTR4 | CYP2A6 787/4885HRH1 62/4885CHRNA7 60/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.